{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:58:54Z","timestamp":1793213934813,"version":"4.5.0"},"reference-count":110,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.blre.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T12:35:04Z","timestamp":1532522104000},"page":"63-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care"],"prefix":"10.1016","volume":"33","author":[{"given":"Moussab","family":"Damlaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4498-3865","authenticated-orcid":false,"given":"Riad","family":"El Fakih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh K.","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2018.07.003_bb0005","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \u201csilver tsunami\u201d: prevalence trajectories and comorbidity burden among older cancer survivors in the United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.blre.2018.07.003_bb0010","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3322\/caac.21349","article-title":"Cancer treatment and survivorship statistics, 2016","volume":"66","author":"Miller","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2018.07.003_bb0015","series-title":"Cancer treatment and survivorship facts & figures","year":"2012"},{"key":"10.1016\/j.blre.2018.07.003_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.7150\/ijms.3827","article-title":"Cancer survivors in the United States: a review of the literature and a call to action","volume":"9","author":"Valdivieso","year":"2012","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.blre.2018.07.003_bb0025","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2010-10-263095","article-title":"How I treat late effects in adults after allogeneic stem cell transplantation","volume":"117","author":"Savani","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0030","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/bmt.2012.258","article-title":"Surviving the cure: long term followup of hematopoietic cell transplant recipients","volume":"48","author":"Majhail","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2018.07.003_bb0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.bbmt.2014.06.035","article-title":"Lost in transition: the essential need for long-term follow-up clinic for blood and marrow transplantation survivors","volume":"21","author":"Hashmi","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2018.07.003_bb0040","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.bbmt.2016.10.020","article-title":"National Institutes of Health hematopoietic cell transplantation late effects initiative: developing recommendations to improve survivorship and long-term outcomes","volume":"23","author":"Battiwalla","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.blre.2018.07.003_bb0045","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3322\/caac.20121","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2018.07.003_bb0050","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1055-9965.EPI-08-0988","article-title":"Long-term survivors of childhood cancers in the United States","volume":"18","author":"Mariotto","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.blre.2018.07.003_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: late effects of treatment and guidelines for surveillance","volume":"53","author":"Ng","year":"2016","journal-title":"Semin Hematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0060","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0065","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJM197211302872204","article-title":"Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy","volume":"287","author":"Arseneau","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0070","first-page":"758","article-title":"Survival outcome after Hodgkin's disease: a report from the international data base on Hodgkin's disease","volume":"17","author":"Henry-Amar","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1182\/blood.V99.3.850","article-title":"Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait","volume":"99","author":"Kang","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0080","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40\u202fyears after treatment for Hodgkin's lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0085","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0090","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clml.2015.07.638","article-title":"Trends and disparities in cardiovascular mortality among survivors of Hodgkin lymphoma","volume":"15","author":"Al-Kindi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2018.07.003_bb0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2141.2011.08713.x","article-title":"Review of the cardiac long-term effects of therapy for Hodgkin lymphoma","volume":"154","author":"Ng","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0100","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2018.07.003_bb0105","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1182\/blood-2010-06-291328","article-title":"Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation","volume":"117","author":"Galper","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0110","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0115","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1001\/jama.2009.476","article-title":"Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial","volume":"301","author":"Young","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2018.07.003_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","article-title":"Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease","volume":"25","author":"Heidenreich","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0125","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.blre.2018.07.003_bb0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2018.07.003_bb0135","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.2010.32.8427","article-title":"Long-term complications of lymphoma and its treatment","volume":"29","author":"Ng","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0140","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a059221","article-title":"Lung function impairment in long-term survivors of Hodgkin's disease","volume":"6","author":"Lund","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0145","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0272-5231(03)00126-6","article-title":"Pulmonary complications of radiation therapy","volume":"25","author":"Abratt","year":"2004","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0150","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/JCO.2005.08.138","article-title":"Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's lymphoma study group","volume":"23","author":"Behringer","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0155","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood-2007-02-073544","article-title":"Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG)","volume":"111","author":"Sieniawski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0160","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/S1470-2045(09)70258-X","article-title":"Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial","volume":"10","author":"Heutte","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0165","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/bjc.2013.779","article-title":"Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity","volume":"110","author":"Daniels","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0170","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2018.07.003_bb0175","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0180","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0185","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1634\/theoncologist.2017-0004","article-title":"FDA approval summary: Nivolumab for the treatment of relapsed or progressive classical Hodgkin lymphoma","volume":"22","author":"Kasamon","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.blre.2018.07.003_bb0190","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0195","series-title":"NCCN clinical practice guidelines in oncology","author":"Lymphoma","year":"2017"},{"key":"10.1016\/j.blre.2018.07.003_bb0200","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0205","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andre","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0210","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0215","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0220","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1093\/jnci\/85.23.1932","article-title":"Second cancers among long-term survivors of non-Hodgkin's lymphoma","volume":"85","author":"Travis","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2018.07.003_bb0225","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","article-title":"The risk of secondary malignancies over 30\u202fyears after the treatment of non-Hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0230","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.2005.04.2200","article-title":"Risk of second malignancy after non-Hodgkin's lymphoma: a British Cohort Study","volume":"24","author":"Mudie","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0235","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2018.07.003_bb0240","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2007.14.6068","article-title":"Risk of subsequent solid tumors after non-Hodgkin's lymphoma: effect of diagnostic age and time since diagnosis","volume":"26","author":"Hemminki","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0245","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1054\/bjoc.1999.1102","article-title":"Second primary neoplasms following non-Hodgkin's lymphoma in New South Wales, Australia","volume":"82","author":"Brennan","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0250","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/annonc\/mdl399","article-title":"Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors","volume":"18","author":"Sanna","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0255","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-08-3392","article-title":"Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma","volume":"107","author":"Moser","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0260","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","article-title":"Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults","volume":"22","author":"Hequet","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0265","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1093\/humrep\/dei018","article-title":"Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma","volume":"20","author":"Dann","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.blre.2018.07.003_bb0270","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/10428190500353877","article-title":"Fertility status among women treated for aggressive non-Hodgkin's lymphoma","volume":"47","author":"Elis","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2018.07.003_bb0275","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/annonc\/mdv227","article-title":"Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma","volume":"26","author":"Meissner","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bjc.6604892","article-title":"Gonadal function in male patients after treatment for malignant lymphomas, with emphasis on chemotherapy","volume":"100","author":"Kiserud","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0285","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood-2017-09-804641","article-title":"Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial","volume":"131","author":"Bartlett","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0290","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/bjh.14870","article-title":"Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies","volume":"179","author":"Rule","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0295","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","article-title":"A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)","volume":"28","author":"Martin","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0300","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2018.07.003_bb0305","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","volume":"2017","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2018.07.003_bb0310","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2018.07.003_bb0315","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0320","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0325","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"4","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0330","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0335","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0340","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11899-016-0309-2","article-title":"Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"11","author":"Caldemeyer","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2018.07.003_bb0345","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/cncr.24257","article-title":"Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy","volume":"115","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0350","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2018.07.003_bb0355","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1182\/blood-2011-06-362889","article-title":"Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0360","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.3324\/haematol.2017.169532","article-title":"Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia","volume":"102","author":"Gugliotta","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.07.003_bb0365","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","article-title":"Quality of life and long-term therapy in patients with chronic myeloid leukemia","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.blre.2018.07.003_bb0370","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","article-title":"Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry","volume":"122","author":"Hoglund","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.blre.2018.07.003_bb0375","doi-asserted-by":"crossref","first-page":"S167","DOI":"10.1007\/s00277-015-2317-z","article-title":"Managing pregnancy in chronic myeloid leukaemia","volume":"94","author":"Palani","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0380","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0385","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","article-title":"Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases","volume":"32","author":"Breccia","year":"2008","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2018.07.003_bb0390","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0395","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1001\/jamaoncol.2016.5688","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study","volume":"3","author":"Global Burden of Disease Cancer C","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0400","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bjh.13537","article-title":"Trends in survival of multiple myeloma patients in Germany and the United States in the first decade of the 21st century","volume":"171","author":"Pulte","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0405","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","article-title":"Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States","volume":"1","author":"Costa","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2018.07.003_bb0410","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0415","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0420","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","article-title":"Fracture risk with multiple myeloma: a population-based study","volume":"20","author":"Melton","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.blre.2018.07.003_bb0425","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1188\/08.CJON.S1.53-62","article-title":"Steroid-associated side effects in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"Faiman","year":"2008","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.blre.2018.07.003_bb0430","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2018.07.003_bb0435","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0440","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2018.07.003_bb0445","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0450","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10\u202fyr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0455","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.blre.2018.07.003_bb0460","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2018.07.003_bb0465","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","article-title":"Next-generation multiple myeloma treatment: a pharmacoeconomic perspective","volume":"128","author":"Rajkumar","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2018.07.003_bb0470","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00520-014-2123-5","article-title":"Unmet psychosocial needs in haematological cancer: a systematic review","volume":"22","author":"Swash","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.hemonc.2018.01.005","article-title":"Damocles' syndrome revisited: update on the fear of cancer recurrence in the complex world of today's treatments and survivorship","author":"Cupit-Link","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.blre.2018.07.003_bb0480","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11764-008-0055-0","article-title":"Health-related information needs in a large and diverse sample of adult cancer survivors: implications for cancer care","volume":"2","author":"Beckjord","year":"2008","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.blre.2018.07.003_bb0485","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/cncr.20560","article-title":"Under use of necessary care among cancer survivors","volume":"101","author":"Earle","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0490","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3322\/caac.20142","article-title":"Survivorship care plans in research and practice","volume":"62","author":"Salz","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2018.07.003_bb0495","series-title":"Guidelines in survivorship. NCCN clinical practice guidelines in oncology","year":"2018"},{"key":"10.1016\/j.blre.2018.07.003_bb0500","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.2013.51.7540","article-title":"Provision and discussion of survivorship care plans among cancer survivors: results of a nationally representative survey of oncologists and primary care physicians","volume":"32","author":"Blanch-Hartigan","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0505","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/bjc.2014.505","article-title":"Survivorship care plans in cancer: a systematic review of care plan outcomes","volume":"111","author":"Brennan","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0510","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/0284186X.2016.1266080","article-title":"The impact of cancer survivorship care plans on patient and health care provider outcomes: a current perspective","volume":"56","author":"van de Poll-Franse","year":"2017","journal-title":"Acta Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0515","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/pbc.22696","article-title":"Increasing rates of breast cancer and cardiac surveillance among high-risk survivors of childhood Hodgkin lymphoma following a mailed, one-page survivorship care plan","volume":"56","author":"Oeffinger","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0520","series-title":"ASH annual meeting","article-title":"Individualized treatment summaries and survivorship care plans (SCPs) for hematopoietic cell transplant (HCT) survivors reduces cancer treatment distress in a randomized, multicenter study","author":"Majhail EAM","year":"2017"},{"key":"10.1016\/j.blre.2018.07.003_bb0525","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/bmt.2012.5","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"47","author":"Majhail","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.blre.2018.07.003_bb0530","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.blre.2018.07.003_bb0535","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2018.07.003_bb0540","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0545","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.2016.68.5206","article-title":"Management of chronic pain in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"34","author":"Paice","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2018.07.003_bb0550","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2013.49.2678","article-title":"Fertility preservation for patients with cancer: American society of clinical oncology clinical practice guideline update","volume":"31","author":"Loren","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18300353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X18300353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T04:11:18Z","timestamp":1571631078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X18300353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":110,"alternative-id":["S0268960X18300353"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2018.07.003","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of survivorship in lymphoma, myeloma and leukemia: Metamorphosis of the field into long term follow-up care","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}